Article Hero

Bayer fell short on revenue

1596627364.jpg
Miguel A. Rodriguez
Miguel A. Rodriguez
14 September 2020
A disappointing Q2 for Bayer

One of the world's most recognized pharmaceutical companies, the German conglomerate Bayer, posted its quarterly earnings, and the figures came in lower-than-expected.

Bayer posted earnings per share of €2.67, and revenue of €10.05 billion, underperforming analysts' expectations. The consensus forecasted €10.57 billion worth of revenue and an EPS of €1.5.  

Its quarterly sales dropped from a previous €13 billion to €11 billion. 

Revenues from the Pharmaceutical segment slipped 8.8% to €3.992 million, as some treatments got postponed due to the pandemic. Among the most affected are ophthalmic and radiological products. 

Bayer offered further guidance. It expects that the growth in sales will reach a high of €44 billion, from a previous top of €45 billion. Also, the EPS is seen at a high of €6.90, downgraded from a prior high of €7.20. 

Since the beginning of the year, Bayer stocks dropped by 21%, while Germany30 lost 4.89%.

CAPEX.com brings you the latest financial news!

Sources: finance.yahoo.com, investing.com

disclaimers_articles

article_share_title

article_rating_title

awful
ok
great
awesome

read_more

Miguel A. Rodriguez
Miguel A. Rodriguez
financial_writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.